Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve

Journal of Assisted Reproduction and Genetics

Volumn 25, Issue 11-12, 2008, Pages 515-521

  Lekamge, Dharmawijaya N ^a,b   Lane, Michelle ^a,b   Gilchrist, Robert B ^a   Tremellen, Kelton P ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Repromed   (Australia)

Author keywords

Anti M llerian hormone; FSH dose adjustment; IVF; Predicted poor ovarian reserve controlled ovarian hyper stimulation

Indexed keywords

CHORIONIC GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; NAFARELIN ACETATE; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; BODY MASS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OVARY CYCLE; OVARY FOLLICLE; OVARY FUNCTION; PREGNANCY OUTCOME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 57349103075     PISSN: 10580468     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10815-008-9266-6     Document Type: Article

References (39)

1. MJ De Vries P De Sutter M Dhont 1999 Prognostic factors in patients continuing in vitro fertilization or intracytoplasmic sperm injection treatment and dropouts Fertil Steril. 72 674 8
2. V Sharma V Allgar M Rajkhowa 2002 Factors influencing the cumulative conception rate and discontinuation of in vitro fertilization treatment for infertility Fertil Steril. 78 40 6
3. B Popovic-Todorovic A Loft HE Bredkjaeer S Bangsboll IK Nielsen AN Andersen 2003 A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment Hum Reprod. 18 2275 82
4. C Pantos SJ Thornton AL Speirs I Johnston 1990 Increasing the human menopausal gonadotropin dose-does the response really improve? Fertil Steril 53 436 9
5. B Popovic-Todorovic A Loft A Lindhard S Bangsboll AM Andersson AN Andersen 2003 A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram Hum Reprod 18 781 7
6. DB Seifer DT Maclaughlin 2007 Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance Fertil Steril. 88 539 46
7. A de Vet JS Laven FH de Jong AP Themmen BC Fauser 2002 Antimullerian hormone serum levels: a putative marker for ovarian aging Fertil Steril. 77 357 62
8. S Muttukrishna H McGarrigle R Wakim I Khadum DM Ranieri P Serhal 2005 Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG. 112 1384 90
9. M McIlveen JD Skull WL Ledger 2007 Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population Hum Reprod. 22 778 85
10. IA van Rooij FJ Broekmans ER te Velde BC Fauser LF Bancsi FH de Jong 2002 Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve Hum Reprod. 17 3065 71
11. DB Seifer DT MacLaughlin BP Christian B Feng RM Shelden 2002 Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles Fertil Steril. 77 468 71
12. A Hazout P Bouchard DB Seifer P Aussage AM Junca P Cohen-Bacrie 2004 Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol Fertil Steril. 82 1323 9
13. S Muttukrishna H Suharjono H McGarrigle M Sathanandan 2004 Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients? BJOG. 111 1248 53
14. T Eldar-Geva A Ben-Chetrit IM Spitz R Rabinowitz E Markowitz T Mimoni 2005 Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome Hum Reprod. 20 3178 83
15. KP Tremellen M Kolo A Gilmore DN Lekamge 2005 Anti-mullerian hormone as a marker of ovarian reserve Aust N Z J Obstet Gynaecol. 45 20 4
16. J Penarrubia F Fabregues D Manau M Creus G Casals R Casamitjana 2005 Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment Hum Reprod. 20 915 22
17. C Ficicioglu T Kutlu E Baglam Z Bakacak 2006 Early follicular antimullerian hormone as an indicator of ovarian reserve Fertil Steril. 85 592 6
18. SM Nelson RW Yates R Fleming 2007 Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy Hum Reprod. 22 2414 21
19. DN Lekamge M Barry M Kolo M Lane RB Gilchrist KP Tremellen 2007 Anti-Mullerian hormone as a predictor of IVF outcome Reprod Biomed Online. 14 602 10
20. A La Marca S Giulini A Tirelli E Bertucci T Marsella S Xella 2007 Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology Hum Reprod. 22 766 71
21. JM Smeenk FC Sweep GA Zielhuis JA Kremer CM Thomas DD Braat 2007 Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection Fertil Steril. 87 223 6
22. H Lashen W Ledger A Lopez Bernal B Evans D Barlow 1998 Superovulation with a high gonadotropin dose for in vitro fertilization: is it effective? J Assist Reprod Genet. 15 438 43
23. RF Harrison S Jacob H Spillane E Mallon B Hennelly 2001 A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-beta) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles Fertil Steril. 75 23 31
24. HJ Out S Lindenberg AL Mikkelsen T Eldar-Geva DL Healy A Leader 1999 A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation Hum Reprod. 14 622 7
25. EH Hoomans BB Mulder 2002 A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI J Assist Reprod Genet. 19 470 6
26. PY Yong S Brett DT Baird KJ Thong 2003 A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment Fertil Steril. 79 308 15
27. K Pruksananonda S Suwajanakorn W Sereepapong P Virutamasen 2004 Comparison of two different fixed doses of follitropin-beta in controlled ovarian hyperstimulation: A prospective randomized, double blind clinical trial J Med Assoc Thai. 87 1151 5
28. B Popovic-Todorovic A Loft S Ziebe AN Andersen 2004 Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in "standard" patients treated with 150 IU/day during the first cycle Acta Obstet Gynecol Scand. 83 842 9
29. CL Cook Y Siow S Taylor ME Fallat 2000 Serum mullerian-inhibiting substance levels during normal menstrual cycles Fertil Steril. 73 859 61
30. A La Marca S Malmusi S Giulini LF Tamaro R Orvieto P Levratti 2004 Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation Hum Reprod. 19 2738 41
31. WJ Hehenkamp CW Looman AP Themmen FH de Jong ER Te Velde FJ Broekmans 2006 Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation J Clin Endocrinol Metab. 91 4057 63
32. R Fanchin J Taieb DH Lozano B Ducot R Frydman J Bouyer 2005 High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status Hum Reprod. 20 923 7
33. JA Land MI Yarmolinskaya JC Dumoulin JL Evers 1996 High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome Fertil Steril. 65 961 5
34. ER Klinkert FJ Broekmans CW Looman JD Habbema ER te Velde 2005 Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial Hum Reprod. 20 611 5
35. L Pal S Jindal BR Witt N Santoro 2008 Less or more; increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilisation Fertil Steril. 89 6 1694 701
36. D Loutradis P Drakakis E Vomvolaki A Antsaklis 2007 Different ovarian stimulation protocols for women with diminished ovarian reserve J Assist Reprod Genet. 24 597 611
37. A Gougeon 1996 Regulation of ovarian follicular development in primates: facts and hypotheses Endocr Rev. 17 121 55
38. A La Marca A Volpe 2006 Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol (Oxf). 64 603 10
39. TH Lee CH Liu CC Huang YL Wu YT Shih HN Ho 2008 Serum anti-mullerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles Hum Reprod. 23 160 7